IDYA reports Q4 net loss $34M, cash $632.6M; multiple 2024 milestones

IDEAYA Biosciences, Inc.

2023-FY EPS reported -$1.96 revenue$23,385,000

Cash $632.6M at Dec 31, 2023; Jan 2024 ATM raised ~$352M gross ($342.3M net); runway into 2028.
Q4 net loss $34.0M (vs $24.2M); FY 2023 net loss $113.0M (vs $58.7M). R&D spend $38.8M Q4.
Targeting two Phase 2 efficacy updates for darovasertib in neoadjuvant uveal melanoma mid-2024, plus FDA guidance.
Gilead collaboration to evaluate IDE397 + Trodelvy in MTAP-deletion bladder cancer; FPI mid-2024.
Werner helicase IND filing targeted 2024; $7M milestone on clearance. GSK collaboration.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

IDEAYA Biosciences, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.

Period: the fourth quarter and full year ended December 31, 2023
Result: reported results

Exact text from the filing

On February 20, 2024, IDEAYA Biosciences, Inc. (the “Company”) announced its financial results for the fourth quarter and full year ended December 31, 2023.

View on SEC.gov

710 earnings releases filed in the last 30 days. Browse all earnings releases →

IDEAYA Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-016758

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.